Androgen receptor signaling pathways as a target for breast cancer treatment

Elisabetta Pietri, Vincenza Conteduca, Daniele Andreis, Ilaria Massa, Elisabetta Melegari, Samanta Sarti, Lorenzo Cecconetto, Alessio Schirone, Sara Bravaccini, Patrizia Serra, Anna Fedeli, Roberta Maltoni, Dino Amadori, Ugo De Giorgi, Andrea Rocca

Research output: Contribution to journalReview article

Abstract

The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on breast range from physiological pubertal development and age-related modifications to cancer onset and proliferation. The prevalence of AR in early breast cancer is around 60%, and AR is more frequently expressed in ER-positive than in ER-negative tumors. We offer an overview of AR signaling pathways in different breast cancer subtypes, providing evidence that its oncogenic role is likely to be different in distinct biological and clinical scenarios. In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/ AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors. Only the ongoing and future prospective clinical trials will allow us to establish which agents are the best option in every specific condition, keeping in mind that there is evidence of opposite androgens and AR agonist/antagonist drug effects on cell proliferation particularly in AR-positive/ER-positive tumors.

Original languageEnglish
Pages (from-to)R485-R498
JournalEndocrine-Related Cancer
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Androgen Receptors
Breast Neoplasms
Androgen Receptor Antagonists
Neoplasms
Triple Negative Breast Neoplasms
Androgens
Phosphatidylinositol 3-Kinases
Transcriptome
Breast
Transcription Factors

Keywords

  • Androgen receptor
  • Androgen receptor structure
  • AR-targeting therapy
  • Breast cancer
  • Signaling pathway

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Androgen receptor signaling pathways as a target for breast cancer treatment. / Pietri, Elisabetta; Conteduca, Vincenza; Andreis, Daniele; Massa, Ilaria; Melegari, Elisabetta; Sarti, Samanta; Cecconetto, Lorenzo; Schirone, Alessio; Bravaccini, Sara; Serra, Patrizia; Fedeli, Anna; Maltoni, Roberta; Amadori, Dino; De Giorgi, Ugo; Rocca, Andrea.

In: Endocrine-Related Cancer, Vol. 23, No. 10, 01.10.2016, p. R485-R498.

Research output: Contribution to journalReview article

Pietri, Elisabetta ; Conteduca, Vincenza ; Andreis, Daniele ; Massa, Ilaria ; Melegari, Elisabetta ; Sarti, Samanta ; Cecconetto, Lorenzo ; Schirone, Alessio ; Bravaccini, Sara ; Serra, Patrizia ; Fedeli, Anna ; Maltoni, Roberta ; Amadori, Dino ; De Giorgi, Ugo ; Rocca, Andrea. / Androgen receptor signaling pathways as a target for breast cancer treatment. In: Endocrine-Related Cancer. 2016 ; Vol. 23, No. 10. pp. R485-R498.
@article{ebb124bd8e92443cb8b14a08c42f2d3a,
title = "Androgen receptor signaling pathways as a target for breast cancer treatment",
abstract = "The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on breast range from physiological pubertal development and age-related modifications to cancer onset and proliferation. The prevalence of AR in early breast cancer is around 60{\%}, and AR is more frequently expressed in ER-positive than in ER-negative tumors. We offer an overview of AR signaling pathways in different breast cancer subtypes, providing evidence that its oncogenic role is likely to be different in distinct biological and clinical scenarios. In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/ AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors. Only the ongoing and future prospective clinical trials will allow us to establish which agents are the best option in every specific condition, keeping in mind that there is evidence of opposite androgens and AR agonist/antagonist drug effects on cell proliferation particularly in AR-positive/ER-positive tumors.",
keywords = "Androgen receptor, Androgen receptor structure, AR-targeting therapy, Breast cancer, Signaling pathway",
author = "Elisabetta Pietri and Vincenza Conteduca and Daniele Andreis and Ilaria Massa and Elisabetta Melegari and Samanta Sarti and Lorenzo Cecconetto and Alessio Schirone and Sara Bravaccini and Patrizia Serra and Anna Fedeli and Roberta Maltoni and Dino Amadori and {De Giorgi}, Ugo and Andrea Rocca",
year = "2016",
month = "10",
day = "1",
doi = "10.1530/ERC-16-0190",
language = "English",
volume = "23",
pages = "R485--R498",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "10",

}

TY - JOUR

T1 - Androgen receptor signaling pathways as a target for breast cancer treatment

AU - Pietri, Elisabetta

AU - Conteduca, Vincenza

AU - Andreis, Daniele

AU - Massa, Ilaria

AU - Melegari, Elisabetta

AU - Sarti, Samanta

AU - Cecconetto, Lorenzo

AU - Schirone, Alessio

AU - Bravaccini, Sara

AU - Serra, Patrizia

AU - Fedeli, Anna

AU - Maltoni, Roberta

AU - Amadori, Dino

AU - De Giorgi, Ugo

AU - Rocca, Andrea

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on breast range from physiological pubertal development and age-related modifications to cancer onset and proliferation. The prevalence of AR in early breast cancer is around 60%, and AR is more frequently expressed in ER-positive than in ER-negative tumors. We offer an overview of AR signaling pathways in different breast cancer subtypes, providing evidence that its oncogenic role is likely to be different in distinct biological and clinical scenarios. In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/ AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors. Only the ongoing and future prospective clinical trials will allow us to establish which agents are the best option in every specific condition, keeping in mind that there is evidence of opposite androgens and AR agonist/antagonist drug effects on cell proliferation particularly in AR-positive/ER-positive tumors.

AB - The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on breast range from physiological pubertal development and age-related modifications to cancer onset and proliferation. The prevalence of AR in early breast cancer is around 60%, and AR is more frequently expressed in ER-positive than in ER-negative tumors. We offer an overview of AR signaling pathways in different breast cancer subtypes, providing evidence that its oncogenic role is likely to be different in distinct biological and clinical scenarios. In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/ AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors. Only the ongoing and future prospective clinical trials will allow us to establish which agents are the best option in every specific condition, keeping in mind that there is evidence of opposite androgens and AR agonist/antagonist drug effects on cell proliferation particularly in AR-positive/ER-positive tumors.

KW - Androgen receptor

KW - Androgen receptor structure

KW - AR-targeting therapy

KW - Breast cancer

KW - Signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=84993981955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993981955&partnerID=8YFLogxK

U2 - 10.1530/ERC-16-0190

DO - 10.1530/ERC-16-0190

M3 - Review article

AN - SCOPUS:84993981955

VL - 23

SP - R485-R498

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 10

ER -